Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Sandoz’s Hyrimoz to challenge AbbVie’s Humira dominance

By Brian Buntz | March 21, 2023

Humira

A robotic arm transfers Humira pens from the conveyor to two-pack cartons. [Image from AbbVie]

The generic and biosimilar company Sandoz, a Novartis (NYSE:SIX) subsidiary, has received FDA approval for its Humira biosimilar Hyrimoz (adalimumab-adaz) injection. AbbVie’s (NYSE:ABBV) megablockbuster Humira is a biologic medication with indications for an array of autoimmune conditions, including rheumatoid arthritis, Crohn’s disease and psoriasis. Sandoz’s biosimilar will likely be priced significantly lower than Humira’s. This fact could dramatically impact the marketplace for AbbVie’s version of the drug, as it is priced lower and could lead to a decrease in market share for Humira.

The FDA approved Sandoz’s Hyrimoz, a biosimilar of AbbVie’s Humira, to treat seven conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

It scored its first FDA approval on December 31, 2002, for rheumatoid arthritis. 

Sandoz plans to launch the product in the U.S. on July 1, 2023.

Earlier this month, the company announced plans to invest $400 million in biomanufacturing facilities in Slovenia. 

The adalimumab biosimilar market is poised to grow at an annual rate of 24%, according to Data Bridge Market Research. 

Background on adalimumab

Adalimumab has been a cash cow for AbbVie. First approved in 2002 under the brand Humira, adalimumab generated $21.24 billion in revenue in 2022, accounting for roughly 37% of AbbVie’s total net revenues. 

AbbVie CEO Rick Gonzalez said in the company’s Q4 2022 earnings call that the company planned on dealing with growing adalimumab biosimilar competition for extending the indications for the monoclonal antibody Skyrizi (risankizumab) is a monoclonal antibody and the Janus kinase (JAK) inhibitor Rinvoq (upadacitinib). The new indications would span “all of Humira’s major indications, plus a distinct new indication, atopic dermatitis,” Gonzalez said. “We anticipate these two products will collectively exceed the peak revenues achieved by Humira by 2027, with significant growth expected through the end of the decade.” Gonzalez also noted that the company was increasing its portfolio of heme and solid tumor candidates for oncology. 

AbbVie believes it is well-placed to deal with the impact of the Humira loss of exclusivity and return to “robust sales growth” in 2025, Gonzalez added. 

Impact on the marketplace

Analysts project that Humira biosimilars could save patients and payers billions of dollars each year.

AbbVie is now facing biosimilar competition for adalimumab in Europe and the U.S. The availability of a biosimilar version of adalimumab in the U.S. could potentially have a significant impact on the marketplace for AbbVie’s version of the drug. In Europe, Sandoz is pricing Hyrimoz at €1,144.65 for two prefilled pens or syringes at 40 mg or €3,354.43 for a pack of six. Its price is 21% lower than Humira’s. 

Amgen’s (Nasdaq:AMGN) Amjevita (adalimumab-atto) was the first biosimilar to Humira to win FDA approval. The company plans on introducing Amjevita this year. 

Adeleke Badejo, a senior immunology analyst at GlobalData, highlights some challenges newer treatments face. “With the loss of first-in-class status, newer treatments must not only overcome the natural assurance healthcare providers have acquired with established treatments but also navigate the obstacle of generics and biosimilars within the drug class,” Badejo said. He also observed that the presence of generic biologics might disproportionately affect new therapies.

Using Amgen’s Amjevita as an example, Badejo notes that its launch is a significant event within the Crohn’s disease and inflammatory bowel disease market. But Badejo concludes that the biosimilars may not have a substantial impact on AbbVie’s market position, given the company’s moves to make Rinvoq and Skyrizi “apparent heirs for Humira within immunology.”

Other competitors

Mylan’s (Nasdaq:MYL) Ixifra is another Humira biosimilar. It could hit the market in the European Union this year as well. 

Additionally, MiGenTra is also developing a biosimilar adalimumab candidate, and the first participants in a Phase 1 clinical trial have been dosed. The trial received unconditional approval from the Paul-Ehrlich Institut (PEI) and is being conducted in Germany.

The approval of Sandoz’s Hyrimoz and the development of MiGenTra’s biosimilar candidate are just two examples of the growing biosimilar market. As the biosimilar landscape evolves, patients, healthcare providers, and payers alike can expect increased competition and potentially more accessible treatment options for various conditions.


Filed Under: Drug Discovery and Development, Gastroenterology, Rheumatology
Tagged With: AbbVie, adalimumab, Amgen, atopic dermatitis, biologics, biomanufacturing, biosimilar, biosimilars, Crohn's disease, generic, Humira, Hyrimoz, psoriasis, rheumatoid arthritis, sandoz
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Unlocking PROTAC potential through better delivery
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
A pharmaceutical technician performs aseptic compounding inside a sterile biosafety cabinet, preparing a cell culture for biologic drug development under strict quality control conditions.
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The division of the staff into two divisions of the company. Mass layoffs, work optimization and cost reduction. Crisis and downsizing of business. Reduce and save business. Keep the best employees.
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE